Objective To investigate the research status, hotspots, and trends in PIK3CA gene mutations in metastatic colorectal cancer (mCRC).

Method Relevant literature on PIK3CA gene mutations in mCRC was retrieved from the Web of Science Core Collection, covering the period from database inception to July 17, 2025. CiteSpace (version 6.3.R1) was employed to conduct visual analyses of annual publication volume, citation counts, countries, institutions, and keywords. Additionally, keyword co-occurrence, a clustering and burst analyses were carried out.

Results A total of 514 publications were included. The annual publication volume exhibited a generally stable trend over time. The University of Texas System was the most productive institution. The United States ranked first in both publication count and centrality. Currently, research hotspots include the mechanistic role of PIK3CA in mCRC, its involvement in therapy and resistance, and the application of liquid biopsy technologies.

Conclusion The PIK3CA gene holds significant therapeutic potential in mCRC. Further investigation into PIK3CA-related molecular mechanisms and the development of combinatorial treatment strategies may offer novel approaches for the clinical management of this disease.

1. SungH, FerlayJ, SiegelRL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.

2. VasanN, BaselgaJ, HymanDM. A view on drug resistance in cancer[J]. Nature, 2019, 575 (7782): 299-309. DOI: 10.1038/s41586-019-1730-1.

3. SiravegnaG, MarsoniS, SienaS, et al. Integrating liquid biopsies into the management of cancer[J]. Nat Rev Clin Oncol, 2017, 14 (9): 531-548. DOI: 10.1038/nrclinonc.2017.14.

4. ParikhAR, LeshchinerI, ElaginaL, et al. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers[J]. Nat Med, 2019, 25 (9): 1415-1421. DOI: 10.1038/s41591-019-0561-9.

5. De RoockW, ClaesB, BernasconiD, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis[J]. Lancet Oncol, 2010, 11(8): 753-762. DOI: 10.1016/S1470-2045(10)70130-3.

6. Sartore-BianchiA, Di NicolantonioF, NichelattiM, et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer[J]. PLoS One, 2009, 4(10): e7287. DOI: 10.1371/journal.pone.0007287.

7. AmadoRG, WolfM, PeetersM, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer[J]. J Clin Oncol, 2008, 26(10): 1626-34. DOI: 10.1200/JCO.2007.14.7116.

8. DouillardJY, OlinerKS, SienaS, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer[J]. N Engl J Med, 2013, 369(11): 1023-1034. DOI: 10.1056/NEJMoa1305275.

9. Di NicolantonioF, MartiniM, MolinariF, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer[J]. J Clin Oncol, 2008, 26(35): 5705-5712. DOI: 10.1200/JCO.2008.18.0786.

10. 陈悦, 陈超美, 刘则渊, 等. CiteSpace知识图谱的方法论功能[J]. 科学学研究, 2015, 33 (2): 242-253.ChenY, ChenCM, LiuZY, et al. The methodology function of CiteSpace mapping knowledge domains[J]. Studies in Science of Science, 2015, 33(2): 242-253. DOI: 10.16192/j.cnki.1003-2053.2015.02.009.

11. 齐虹, 闫静璇. 基于知识图谱的我国信息行为研究态势分析[J]. 现代情报, 2018, 38(5): 131-139.QiH, YanJX. Analysis of information behavior research situation in China based on knowledge map[J]. Journal of Modern Information, 2018, 38(5): 131-139. DOI: 10.3969/j.issn.1008-0821.2018.05.021.

12. PolivkaJJr, JankuF. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway[J]. Pharmacol Ther, 2014, 142(2): 164-175. DOI: 10.1016/j.pharmthera.2013.12.004.

13. AfrăsânieVA, MarincaMV, GaftonB, et al. Clinical, pathological and molecular insights on KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in metastatic colorectal cancer patients from Northeastern Romania[J]. Int J Mol Sci, 2023, 24(16): 12679. DOI: 10.3390/ijms241612679.

14. VoutsadakisIA. PIK3CA mutated colorectal cancers without KRAS, NRAS and BRAF mutations possess common and potentially targetable mutations in epigenetic modifiers and DNA damage response genes[J]. Cancer Genomics Proteomics, 2024, 21(5): 533-548. DOI: 10.21873/cgp.20470.

15. ShinAE, SugiuraK, KariukiSW, et al. LIN28B-mediated PI3K/AKT pathway activation promotes metastasis in colorectal cancer models[J]. J Clin Invest, 2025, 135(8): e186035. DOI: 10.1172/JCI186035.

16. LiuY, ZhaiYP, ZhangY, et al. High metastatic tumor-derived CXCL16 mediates liver colonization metastasis by inducing Kupffer cell polarization via the PI3K/AKT/FOXO3a pathway[J]. Neoplasia, 2025, 65: 101174. DOI: 10.1016/j.neo.2025.101174.

17. WangR, LiW, LvY, et al. Colorectal cancer cells-derived exosomal PIK3CA mutation DNA promotes tumor metastasis by activating fibroblast and affecting tumor metastatic microenvironment[J]. Adv Sci (Weinh), 2025, 12 (27): e2501792. DOI: 10.1002/advs.202501792.

18. LiuYL, XiangZ, ZhangBY, et al. APOA5 alleviates reactive oxygen species to promote oxaliplatin resistance in PIK3CA-mutated colorectal cancer[J]. Aging (Albany NY), 2024, 16(11): 9410-9436. DOI: 10.18632/aging.205872.

19. ZhuM, JinQ, XinY. Recent clinical advances in PI3K inhibitors on colorectal cancer[J]. Pharmazie, 2021, 76(12): 568-573. DOI: 10.1691/ph.2021.1820.

20. RachiglioAM, ForgioneL, PasqualeR, et al. Dynamics of RAS/BRAF mutations in cfDNA from metastatic colorectal carcinoma patients treated with polychemotherapy and anti-EGFR monoclonal antibodies[J]. Cancers (Basel), 2022, 14(4): 1052. DOI: 10.3390/cancers14041052.

21. LimAR, KimB, KimJH, et al. Phase Ib and pharmacokinetics study of alpelisib, a PIK3CA inhibitor, and capecitabine in patients with advanced solid tumors[J]. Front Oncol, 2024, 14 1390452. DOI: 10.3389/fonc.2024.1390452.

22. VoutsadakisIA. Sensitivities and dependencies of BRAF mutant colorectal cancer cell lines with or without PIK3CA mutations for discovery of vulnerabilities with therapeutic potential[J]. Medicina (Kaunas), 2022, 58(10): 1498. DOI: 10.3390/medicina58101498.

23. García-RomanS, Garzón-IbáñezM, Bertrán-AlamilloJ, et al. Vaccine antibodies against a synthetic epidermal growth factor variant enhance the antitumor effects of inhibitors targeting the MAPK/ERK and PI3K/Akt pathways[J]. Transl Oncol, 2024, 40: 101878. DOI: 10.1016/j.tranon.2024.101878.

24. MaL, AiF, XiaoH, et al. Lycium barbarum polysaccharide reverses drug resistance in oxaliplatin-resistant colon cancer cells by inhibiting PI3K/AKT-dependent phosphomannose isomerase[J]. Front Pharmacol, 2024, 15: 1367747. DOI: 10.3389/fphar.2024.1367747.

25. LuoB, LiaoM, NieB, et al. Genomic profiles and their associations with microsatellite instability status, tumor mutational burden, and programmed death ligand 1 expression in Chinese patients with colorectal cancer[J]. J Gastrointest Oncol, 2024, 15(6): 2460-2472. DOI: 10.21037/jgo-24-748.

26. MatteucciL, SulloFG, GallioC, et al. Multigene panel next-generation sequencing techniques in the management of patients with metastatic colorectal carcinoma: the way forward for personalized treatment? A single-center experience[J]. Int J Mol Sci, 2024, 25(20): 11071. DOI: 10.3390/ijms252011071.

27. LavacchiD, GelminiS, CalabriA, et al. Early changes in circulating tumor DNA (ctDNA) predict treatment response in metastatic KRAS-mutated colorectal cancer (mCRC) patients[J]. Heliyon, 2023, 9(11): e21853. DOI: 10.1016/j.heliyon.2023.e21853.

28. BayleA, BasileD, GarinetS, et al. Next-Generation sequencing targeted panel in routine care for metastatic colon cancers[J]. Cancers (Basel), 2021, 13(22): 5750. DOI: 10.3390/cancers13225750.

29. YamadaT, MatsudaA, TakahashiG, et al. Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy[J]. Int J Clin Oncol, 2020, 25(8):1523-1532. DOI: 10.1007/s10147-020-01691-0.

30. MancaP, CoralloS, BusicoA, et al. The added value of baseline circulating tumor DNA profiling in patients with molecularly hyperselected, left-sided metastatic colorectal cancer[J]. Clin Cancer Res, 2021, 27(9): 2505-2514. DOI: 10.1158/1078-0432.CCR-20-4699.

31. SirajS, MasoodiT, SirajAK, et al. Clonal evolution and timing of metastatic colorectal cancer[J]. Cancers (Basel), 2020, 12(10): 2938. DOI: 10.3390/cancers12102938.